Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- J&J Makes Debut in Japan Lung Cancer Market with Rybrevant Launch
December 2, 2024
- Takeda Suspends Shipments of MR Vaccine as Quality Issue Drags On
December 2, 2024
- Sumitomo’s iPSC-Derived Retinal Sheet Set to Enter Clinic in US
December 2, 2024
- Alfresa Files ARS’ Epinephrine Nasal Spray in Japan
December 2, 2024
- Japan Pharma Market Projected to Cross 12 Trillion Yen in FY2029: IQVIA
November 29, 2024
- Leqembi Now Available in South Korea: Eisai
November 29, 2024
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
- Eisai, NCNP Tie Up for APOE Genetic Testing Research Sponsored by AMED
November 27, 2024
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Otsuka Files Esperion’s Cholesterol Fighter in Japan
November 27, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
November 26, 2024
- Kyowa Kirin Recalls Regpara after Nitrosamine Detection
November 25, 2024
- Keytruda, Arexvy, Imfinzi, Lynparza Broaden Labels in Japan
November 25, 2024
- Otsuka Bags Worldwide Rights to Ionis’ ALS Drug
November 25, 2024
- Takeda’s Fruzaqla Now Available in Japan, AbbVie’s Skyrizi Adds New Version
November 25, 2024
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- COVID as a Lesson, Pfizer Exec Urges Govt to Draft Emergency Safety Management Guidelines
November 22, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…